Belgium· BE-AMP-SAM590506-00
Xeljanz 1 mg/ml
A tofacitinib product containing tofacitinib citrate, registered in Belgium by Pfizer Europe MA. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Tofacitinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AF01 (tofacitinib), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 7 of them publish a price we can compare per daily dose
Tofacitinib · ATC L04AF01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tofacitinib costs, country by country.
Normalised to the WHO defined daily dose (10 mg), the median price runs from $1.99 in United States to $17.31 in Switzerland — a ×8.7 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Tofacitinib · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$17.31
- US United States$1.99 (acquisition cost)
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Tofacitinib Citrate
- Manufacturer
- Pfizer Europe MA
- Country
- Belgium (BE)
- ATC code
- L04AF01
- ATC class
- Tofacitinib
- Defined daily dose
- 10 mg, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
1 priced- be_apb7737638
- be_apb4297115EUR 759.06
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
512 interactions on record for tofacitinib.
Graded by severity as the source publishes them — 333 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Tofacitinib · interactions on record
512 records
- 333 severe
- 171 moderate
- 8 minor
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Tofacitinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesTOFACITINIBNovadoz Pharmaceuticals LLC
- SpainXELJANZ 1 MG/ML SOLUCION ORALPfizer Europe Ma Eeig
- FinlandXeljanzPfizer Europe MA EEIG
- IrelandXELJANZ 1 mg/mL oral solutionPfizer Europe MA EEIG
- IcelandXELJANZPfizer Europe MA EEIG*
- CzechiaXELJANZPfizer Europe MA EEIG, Bruxelles
- NorwayXeljanzPfizer Europe MA EEIG (1)
- PolandXeljanzPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 15 EEA countries. Names it is sold under:
- Austria · Tofacitinib Devatis, Tofacitinib Stada
- Bulgaria · Tофацитиниб Devatis
- Denmark · Tofacitinib Accord, Tofacitinib Newbury
- Spain · Tofacitinib Stada
- Finland · Tofacitinib Devatis, Tofacitinib Stada
- France · Tofacitinib Stada
- United Kingdom (Northern Ireland) · Tofacitinib Amarox, Tofacitinib Brown & Burk Uk
- Croatia · Tofacitinib Accord, Tofacitinib Stada
- Iceland · Xeljanz
- Liechtenstein · Xeljanz
- Malta · Tofacitinib Stada
- Netherlands · Tofacitinib Devatis, Tofacitinib Stada
- Norway · Tofacitinib Accord, Tofacitinib Devatis
- Portugal · Tofacitinib Bluepharma
- Sweden · Tofacitinib Devatis, Tofacitinib Newbury
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3f634999-6d76-49a4-aeb9-f88eaa3e3aea GET /v1/drugs/3f634999-6d76-49a4-aeb9-f88eaa3e3aea?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oral solution",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Xeljanz 1 mg/ml",
"name_fr": "Xeljanz 1 mg/ml",
"name_nl": "Xeljanz 1 mg/ml",
"amp_code": "SAM590506-00",
"strengths": [
"1.0000",
"2.3900",
"0.9000"
],
"pack_count": 1,
"substances": [
"Tofacitinib Citrate",
"Tofacitinib",
"Glycerol",
"Propylene Glycol",
"Sodium Benzoate",
"Xylitol"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Tofacitinib",
"authorisation_numbers": [
"EU/1/17/1178/015"
]
}See everything about tofacitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.